Buy Insmed Incorporated | NASDAQ – INSM | Short Term Trading Advice | Healthcare Sector | 11th Nov 2025 | Expected Gain 4% – 5%

Date

11 November 2025

Analysed By

Naranj Capital Research Desk

Stock Market

NASDAQ, United States of America

Target hit. Trade closed.

NASDAQ INSM

11 Nov 2025

18 Nov 2025

6 days

Loss per
100,000 USD

Stop-loss

180

Buy Advice

11 Nov 2025

188 - 192

Target 1

18 Nov 2025

200

Target 2

18 Nov 2025

202

Profit per
100,000 USD

6 days

7,447

180

188 - 192

200

202

7,447

Short Term Stock Trading Advice in USA

Buy

Buy
Range

Target

Stoploss

Upside
Potential

Trade
Duration

Insmed Incorporated

188 - 192

200 - 202

Below 180

4% – 5%

12 - 14 Days

Buy Insmed Incorporated

Buy
Range 188 - 192

Target 200 - 202

Stoploss Below 180

Upside
Potential 4% – 5%

Trade
Duration 12 - 14 Days

* Once the first target hit, reset the StopLoss at your buying price.

* Trade durations are approximate; actual holding period may vary.

Insmed Incorporated (NASDAQ: INSM) - Stock Overview

NASDAQ Code

Stock Name

Sector

52 Weeks High

52 Weeks Low

INSM

Insmed

Health Care

197.08

60.40

NASDAQ Code INSM

Stock Name Insmed

Sector Health Care

52 Weeks High 197.08

52 Weeks Low 60.40

Company profile

Insmed Incorporated is a U.S.-based biopharmaceutical company developing treatments for serious and rare diseases. Its key product, ARIKAYCE, treats nontuberculous mycobacterial lung infections. The company is also advancing brensocatib for bronchiectasis, treprostinil palmitil inhalation powder for pulmonary hypertension, and a gene therapy for Duchenne muscular dystrophy. Founded in 1988, Insmed is headquartered in Bridgewater, New Jersey.

Insmed Incorporated (NASDAQ: INSM) - Q3 FY25 Financials Highlights

Metric	Q3 2025	Q2 2025	Q3 2024	QoQ Change	YoY Change
1. Total Revenue	$142.3M	$107.4M	$93.4M	+32.5% ↑	+52.4% ↑
2. Gross Profit Margin	79.30%	73.80%	77.30%	+5.5 bps ↑	+2.0 bps ↑
3. R&D + SG&A Expenses	$372.8M	$332.0M	$269.7M	+12.3% ↑	+38.2% ↑
4. Net Loss	$(370.0)M	$(321.7)M	$(220.5)M	-15.0% ↓	-67.8% ↓
5. EPS (Diluted)	$(1.75)	$(1.70)	$(1.27)	-2.9% ↓	-37.8% ↓

Insmed Incorporated (NASDAQ: INSM) - Earnings Call Summary for Q3/2025

Strong Revenue Growth: Revenue rose 52% YoY to $142.3 million, driven by new drug BRINSUPRI, which earned $28.1 million in just six weeks.
ARIKAYCE Growth: Main product ARIKAYCE made $114.3 million, up 22%, with strong gains in Japan and Europe. Full-year guidance raised to $420–430 million.
Net Loss: Reported a $370 million loss ($1.75/share) due to higher R&D and marketing costs for new drugs.
Strong Cash: Holds $1.7 billion in cash, ensuring funding for launches and trials.
Pipeline Progress: New TPIP Phase 3 trial starts Q4 2025; key data for ARIKAYCE and brensocatib expected in early 2026; regulatory filings ongoing in Europe, UK, and Japan.

Insmed Incorporated (NASDAQ: INSM) vs NASDAQ - Relative Performance

The image showcases Insmed's 1-year performance relative to NASDAQ. — Relative Performance - Last 1 Year
INSM — NASDAQ —

Insmed Incorporated (NASDAQ: INSM) - Price Performance

Insmed Incorporated (NASDAQ: INSM) - Technical Analysis (Daily)

The stock earlier underwent a prolonged consolidation phase within a rectangle pattern.
A strong gap-up breakout from this zone triggered a sharp rally, propelling prices significantly higher.
Now trading near its all-time high, the stock continues to exhibit strong bullish momentum and may soon register fresh highs in the coming sessions.